Immatics (NASDAQ:IMTX) Short Interest Update

Immatics (NASDAQ:IMTX) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 10,020,000 shares, an increase of 5.3% from the September 30th total of 9,520,000 shares. Based on an average trading volume of 487,400 shares, the short-interest ratio is presently 20.6 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a report on Thursday, September 5th. Piper Sandler initiated coverage on shares of Immatics in a research note on Monday, October 7th. They issued an “overweight” rating and a $19.00 target price on the stock.

Immatics Stock Performance

NASDAQ IMTX opened at $9.33 on Friday. Immatics has a one year low of $7.80 and a one year high of $13.77. The company has a 50-day simple moving average of $10.81 and a 200-day simple moving average of $11.34. The firm has a market capitalization of $1.11 billion, a PE ratio of -10.48 and a beta of 0.75.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The company had revenue of $20.19 million during the quarter, compared to analyst estimates of $12.36 million. Equities analysts forecast that Immatics will post -0.93 earnings per share for the current year.

Institutional Trading of Immatics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AlphaCentric Advisors LLC raised its holdings in shares of Immatics by 14.3% during the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock valued at $232,000 after acquiring an additional 2,500 shares during the period. Quarry LP acquired a new stake in shares of Immatics during the second quarter valued at approximately $99,000. Forefront Analytics LLC acquired a new stake in shares of Immatics during the second quarter valued at approximately $139,000. Nan Fung Group Holdings Ltd acquired a new stake in shares of Immatics during the first quarter valued at approximately $165,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Immatics by 13.9% during the second quarter. The Manufacturers Life Insurance Company now owns 150,769 shares of the company’s stock valued at $1,752,000 after acquiring an additional 18,354 shares during the period. 64.41% of the stock is owned by institutional investors and hedge funds.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.